# Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan

> **NCT03873116** · PHASE3 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Hereditary Angioedema, HAE

## Interventions

- **DRUG:** BCX7353 capsules
- **DRUG:** BCX7353 capsules
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03873116
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-27
- **Primary completion:** 2021-07-08
- **Final completion:** 2021-07-08
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03873116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03873116, "Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03873116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*